An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Bristol-Myers Squibb
Study ID
NCT03351231
Phase
PHASE1/PHASE2
Status
Terminated

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BMS-986242 — DRUG
    Specified dose on specified days
  • Nivolumab — BIOLOGICAL
    Specified dose on specified days

Study Details

The purpose of this study is to investigate safety of experimental medication BMS-986242 and Nivolumab in patients with advanced cancers.

Key Dates

Start date
Nov 27, 2017
Status verified
Aug 2020
Primary completion
Aug 28, 2018
Completion
Aug 28, 2018

Study Design

Enrollment
7 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Dose Escalation
    BMS-986242 administered in combination with Nivolumab
  • Experimental: Dose Expansion
    BMS-986242 administered in combination with Nivolumab

Primary Outcome Measure

Number of Participants With Adverse Events (AE) [ Time Frame: From initiation of study treatment until 100 days after discontinuation of study treatment ]

Locations (4)

FacilityCityStateZIPSite coordinators
University Of Alabama At BirminghamBirminghamAlabama35294-3300-
Hoag Memorial Hospital PresbyterianLos AngelesCalifornia90033-
USC Norris Comprehensive Cancer CenterLos AngelesCalifornia90033-
Local InstitutionBaltimoreMaryland21287-

Find similar trials in Birmingham, AL

By research site
University Of Alabama At Birmingham· Birmingham, ALHoag Memorial Hospital Presbyterian· Los Angeles, CAUSC Norris Comprehensive Cancer Center· Los Angeles, CALocal Institution· Baltimore, MD

Related Studies